Overview
This registry has been established to gain a better understanding of the clinical and biological characteristics and outcome of patients with lymphoid cancer
Description
Lymphoid cancer including Hodgkin disease, non-Hodgkin lymphomas (NHL) and myeloma, represents the most common hematologic malignancy. Despite the overall prognosis improved in the last 10 years, there are many open issues that need to be addressed, specifically refractoriness to standard treatment, disease recurrence and outcome with new drug in the so called "real world" setting. Since the Hematology and Bone Marrow Transplant Unit at "Ospedale Papa Giovanni XIII" of Bergamo has developed specific tools to collect clinical data thought fully validated electronic charts and biological specimens thanks to a regulatory compliant biobanking program, the aim of this study is to collect clinical and biological information of lymphoid cancer patients. The cohort of patients enrolled will permit to analyze the practice pattern, perform biological correlative studies of great translational potential with relevance to clinical practice.
Eligibility
Inclusion Criteria:
- Male or female patients 18 years or older
- Written informed consent
- Confirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma
Exclusion Criteria:
- Unconfirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma